Human papillomavirus infection and the primary and secondary prevention of cervical cancer.
A wealth of evidence has led to the conclusion that virtually all cases of cervical cancer are attributable to persistent infection by a subset of human papillomavirus (HPV) types, especially HPV type 16 (HPV-16) and HPV-18. These HPV types also cause a proportion of other cancers, including vulvar, vaginal, anal, penile, and oropharyngeal cancers. Although cervical cancer screening, primarily with the Papanicolaou (Pap) smear, has reduced the incidence of this cancer in industrialized countries, cervical cancer remains the second most common cause of death from cancer in women worldwide, because the developing world has lacked the resources for widespread, high-quality screening. In addition to advances in Pap smear technology, the identification of HPV as the etiologic agent has produced 2 recent advances that may have a major impact on approaches to reduce the incidence of this disease. The first is the development of a preventive vaccine, the current versions of which appear to prevent close to 100% of persistent genital infection and disease caused by HPV-16 and HPV-18; future second-generation vaccines may be able to protect against oncogenic infections by a broader array of HPV types. The second is the incorporation of HPV testing into screening programs. In women aged >30 years, HPV testing can identify high-grade cervical intraepithelial neoplasia earlier than Pap smears with acceptable rates of specificity. These results, together with the high sensitivity of HPV testing, suggest that such testing could permit increased intervals for screening. An inexpensive HPV test in development, if successful, may be incorporated as part of an economically viable 'screen-and-treat' approach in the developing world. The manner in which vaccination and screening programs are integrated will need to be considered carefully so that they are efficient in reducing the overall incidence of cervical cancer.
Lowy
Douglas R
DR
Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. lowyd@mail.nih.gov
Solomon
Diane
D
Hildesheim
Allan
A
Schiller
John T
JT
Schiffman
Mark
M
D005260:Female; D052162:Human papillomavirus 16 / Q000235:genetics; D052161:Human papillomavirus 18 / Q000235:genetics; D006801:Humans; D009857:Oncogenes; D065006:Papanicolaou Test; D030361:Papillomavirus Infections / Q000150:complications*; D053918:Papillomavirus Vaccines / Q000276:immunology*; D002583:Uterine Cervical Neoplasms / Q000209:etiology / Q000517:prevention & control*; D014611:Vaccination; D014626:Vaginal Smears
D053918:Papillomavirus Vaccines
N Engl J Med. 2007 Oct 18;357(16):1579-88
17942871
CA Cancer J Clin. 2007 Jan-Feb;57(1):7-28
17237032
Br J Cancer. 2008 Jan 15;98(1):15-21
18182975
J Natl Cancer Inst. 2008 Apr 2;100(7):513-7
18364507
Lancet. 2007 Jun 2;369(9576):1861-1868
17544766
Lancet. 2007 Nov 24;370(9601):1740-2
17919717
Am J Obstet Gynecol. 2007 Oct;197(4):356.e1-6
17904958
Int J Gynaecol Obstet. 2008 Jan;100(1):24-6
17897647
Int J Cancer. 2004 Aug 20;111(2):278-85
15197783
Virology. 2004 Apr 10;321(2):205-16
15051381
Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):326-33
16492924
N Engl J Med. 2007 May 10;356(19):1928-43
17494926
Am J Obstet Gynecol. 2007 Jul;197(1):47.e1-8
17618753
Am J Obstet Gynecol. 2007 Oct;197(4):340-5
17904956
J Virol. 1996 May;70(5):3298-301
8627814
J Infect Dis. 2005 Jun 1;191(11):1796-807
15871111
Lancet. 2007 Nov 24;370(9601):1764-72
17919718
Int J Gynaecol Obstet. 2003 Dec;83(3):311-3
14643047
Obstet Gynecol. 2007 Oct;110(4):833-40
17906017
J Cancer Res Clin Oncol. 2007 Apr;133(4):235-45
17294241
N Engl J Med. 2006 Jun 22;354(25):2645-54
16790697
Front Biosci. 2008 Jan 01;13:1003-17
17981607
Int J Cancer. 2006 Dec 1;119(11):2677-84
16991121
J Natl Cancer Inst Monogr. 2003;(31):41-6
12807944
Cancer Res. 2006 Oct 15;66(20):10112-9
17047075
Gynecol Oncol. 2005 Dec;99(3 Suppl 1):S7-11
16154623
Am J Obstet Gynecol. 2006 Aug;195(2):349-53
16677597
J Biol Chem. 2007 Oct 26;282(43):31803-11
17804402
Annu Rev Immunol. 1997;15:235-70
9143688
J Virol. 1991 Feb;65(2):606-12
1846186
J Natl Cancer Inst Monogr. 2003;(31):97-101
12807952
Lancet Oncol. 2006 Jul;7(7):547-55
16814206
N Engl J Med. 2002 Apr 11;346(15):1105-12
11948269
Cancer Res. 2008 Jan 1;68(1):307-13
18172324
BMC Womens Health. 2007 Oct 01;7:16
17908317
Am J Obstet Gynecol. 2007 Oct;197(4):346-55
17904957
J Gen Virol. 2007 May;88(Pt 5):1460-1469
17412974
Am J Clin Pathol. 2005 Feb;123(2):281-7
15842055
Vaccine. 2006 Aug 31;24 Suppl 3:S3/78-89
16950021
N Engl J Med. 2007 Oct 18;357(16):1589-97
17942872
Br J Cancer. 1999 Aug;80(12):2008-18
10471054
Lancet. 2007 Sep 8;370(9590):890-907
17826171
Clin Cancer Res. 2007 May 1;13(9):2599-605
17473189
J Natl Cancer Inst. 2005 Jul 20;97(14):1072-9
16030305
J Natl Cancer Inst. 2006 Jun 7;98(11):765-74
16757701
J Virol. 1998 Jul;72(7):6151-4
9621080
J Infect Dis. 2007 Jun 1;195(11):1582-9
17471427
J Clin Invest. 2006 May;116(5):1167-73
16670757
Vaccine. 2006 Aug 31;24 Suppl 3:S3/171-7
16844268
Lancet. 2001 Jun 9;357(9271):1831-6
11410191
N Engl J Med. 2005 Nov 17;353(20):2158-68
16291985
Virology. 2005 Jun 20;337(1):76-84
15914222
Int J Cancer. 2006 Sep 1;119(5):1108-24
16570271
Virology. 2004 Jun 20;324(1):17-27
15183049
Lancet. 2007 Jun 30;369(9580):2161-2170
17602732
J Virol. 1992 Apr;66(4):2057-66
1312620
Am J Obstet Gynecol. 2003 Jun;188(6):1383-92
12824967
Int J Cancer. 2006 Mar 15;118(6):1481-95
16206285
Obstet Gynecol. 2008 Jan;111(1):167-77
18165406
Cancer. 2007 Jun 25;111(3):145-53
17487850
Virology. 2000 May 10;270(2):254-7
10792983
Lancet. 2007 May 19;369(9574):1693-702
17512854
JAMA. 2001 Mar 21;285(11):1500-5
11255427
Lancet. 2007 Aug 4;370(9585):398-406
17679017
Clin Vaccine Immunol. 2007 Oct;14(10):1285-95
17687110
Br J Cancer. 2006 Dec 4;95(11):1459-66
17117182
Lancet. 2006 Apr 15;367(9518):1247-55
16631880
Vaccine. 2006 Aug 31;24 Suppl 3:S3/147-53
16950002
Lancet Infect Dis. 2002 Jul;2(7):395-403
12127351
Int J Cancer. 2007 Aug 1;121(3):621-32
17405118
Cancer. 2005 Oct 25;105(5):253-62
15991244
J Virol. 2007 Nov;81(21):11585-92
17715230
Sex Transm Dis. 2004 Oct;31(10):601-7
15388997
Dis Markers. 2007;23(4):315-30
17627065
Virology. 1996 May 1;219(1):37-44
8623552
Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1654-8
7878034
Nat Rev Cancer. 2002 May;2(5):342-50
12044010
N Engl J Med. 2002 Nov 21;347(21):1652-61
12444179
Adv Data. 2005 Sep 15;(362):1-55
16250464
Virology. 2005 Jul 5;337(2):365-72
15885736
J Natl Cancer Inst. 2002 Sep 18;94(18):1406-14
12237286
Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):4-10
17220325
J Virol. 2001 Sep;75(17):7848-53
11483728
Int J Cancer. 2006 Jun 15;118(12):3030-44
16404738
Int J Cancer. 2007 Feb 15;120(4):885-91
17131323
Vaccine. 2005 May 25;23(28):3634-41
15882523
J Pathol. 2006 Jan;208(2):152-64
16362994
JAMA. 2007 Aug 15;298(7):743-53
17699008
Annu Rev Immunol. 2003;21:515-46
12500980
J Virol. 2004 Nov;78(21):11451-60
15479788
Lancet. 2003 Dec 6;362(9399):1871-6
14667741
Clin Cancer Res. 2004 May 1;10(9):3059-63
15131043
J Clin Virol. 2005 Mar;32 Suppl 1:S16-24
15753008
J Infect Dis. 2007 Oct 15;196(8):1137-45
17955431
N Engl J Med. 2005 Nov 17;353(20):2101-4
16291978
Virology. 2000 Feb 15;267(2):141-50
10662610
Lancet. 2006 Jan 14;367(9505):122-32
16413876
Virology. 1995 Aug 1;211(1):204-8
7544045
J Infect Dis. 1995 Jun;171(6):1387-98
7769272
N Engl J Med. 2007 May 10;356(19):1915-27
17494925
Br J Cancer. 2007 Feb 12;96(3):514-8
17245341
Obstet Gynecol. 2006 Aug;108(2):264-72
16880294